The number of cancer cases in France has doubled over 30 years.

Omissions

• The claim uses the crude (absolute) number of new cases. The same official source (Santé publique France) shows that age-standardised incidence has risen much less than the crude count, and among men has been roughly stable — the doubling is largely explained by population growth, ageing and increased detection rather than by a proportional rise in individual risk.
• The exact period covered by the latest official data is 1990–2023 (about 33 years), not exactly 30 years.
• The most recent incidence estimates available before the session date are for 2023 (published 2024–2025); no 2025 or 2026 national incidence data exists yet, so no more recent figure could be used.
• Presenting the crude doubling without the demographic/screening drivers may create a misleading impression of an epidemic of environmental origin, which the underlying source does not support.

Sources

• PrimarySanté publique France — CancersEn 2023, le nombre total de nouveaux cas de cancer est estimé à 433 000 dont 57 % chez l'homme. Ce nombre a doublé depuis 1990. […] L'évolution de l'incidence (taux standardisés sur la structure d'âge de la population mondiale) de l'ensemble des cancers entre 1990 et 2023 diffère selon le sexe […] Chez l'homme, l'incidence standardisée a ainsi peu augmenté alors qu'elle n'a cessé de croître chez la femme.
• PrimaryOECD — EU Country Cancer Profile: France 2025plus de 430 000 nouveaux cas de cancer étaient attendus en France en 2022 […] Because cancer typically occurs in middle and old ages, the evolution of cancer incidence depends on three factors: the ageing of the population, its size and the cancer risk factors to which people have been exposed. From 1990 to 2023, the ageing of the population […]